Themis Medicare Ltd Stock Hits 52-Week Low Amid Continued Downtrend

Stock Price Movement and Market Context

The stock opened the day with a gap down of -3.41% and continued to slide, touching an intraday low of Rs.79.05, representing a -5.39% fall from the previous close. This decline extended a losing streak spanning four consecutive trading sessions, during which Themis Medicare’s share price has dropped by -16.37%. The day’s performance also lagged behind the Pharmaceuticals & Biotechnology sector by -3.51%, underscoring the stock’s relative weakness.

Technical indicators reveal that Themis Medicare is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad-based technical weakness signals sustained selling pressure and a lack of short- to medium-term momentum.

Meanwhile, the broader market has also faced headwinds. The Sensex opened 385.82 points lower and closed down by 241.27 points at 81,553.38, a decline of -0.76%. The index is currently trading below its 50-day moving average, although the 50DMA remains above the 200DMA. The Sensex has recorded a three-week consecutive fall, losing -4.91% over this period, indicating a cautious market environment.

Financial Performance and Profitability Trends

Themis Medicare’s financial results have been under pressure for an extended period. The company has reported negative results for four consecutive quarters, with the latest quarter showing a Profit Before Tax (PBT) excluding other income of Rs. -6.69 crores, a decline of -152.0% compared to the previous four-quarter average. This sharp contraction in profitability has weighed heavily on investor sentiment.

Net sales for the latest six months stood at Rs.175.57 crores, reflecting a contraction of -26.85% year-on-year. Correspondingly, the company posted a net loss after tax (PAT) of Rs. -17.84 crores over the same period, also down by -26.85%. These figures highlight a challenging revenue environment and continued pressure on the bottom line.

Over the last five years, Themis Medicare’s operating profit has declined at an annualised rate of -189.22%, indicating persistent difficulties in generating sustainable earnings growth. This long-term trend has contributed to the stock’s current classification as a Strong Sell, an upgrade from its previous Sell rating as of 1 Feb 2025, reflecting deteriorating fundamentals.

Valuation and Market Perception

The stock’s valuation metrics suggest elevated risk levels. Themis Medicare is trading at valuations that are considered risky relative to its historical averages. Over the past year, the stock has delivered a total return of -68.96%, significantly underperforming the Sensex, which gained 7.50% over the same period. This divergence underscores the company’s struggles amid a generally positive market backdrop.

Despite its market capitalisation grade of 3, indicating a mid-sized company, domestic mutual funds hold no stake in Themis Medicare. Given that domestic mutual funds typically conduct thorough research and maintain positions in companies with stable prospects, their absence from the shareholding pattern may reflect reservations about the company’s current valuation and business outlook.

Comparative Performance and Sectoral Context

Themis Medicare’s underperformance extends beyond the immediate timeframe. The stock has lagged the BSE500 index over the last three years, one year, and three months, highlighting a sustained period of below-par returns. The 52-week high for the stock was Rs.272.05, illustrating the magnitude of the decline to the current low of Rs.79.05.

Within the Pharmaceuticals & Biotechnology sector, Themis Medicare’s relative weakness is notable, especially as the sector has generally shown resilience amid broader market volatility. The stock’s underperformance by -3.51% relative to its sector peers on the day of the new low further emphasises this point.

Balance Sheet and Debt Servicing

On a more positive note, Themis Medicare maintains a relatively strong ability to service its debt obligations. The company’s Debt to EBITDA ratio stands at a modest 0.86 times, indicating manageable leverage levels. This metric suggests that despite the earnings challenges, the company’s debt burden remains contained, which may provide some financial stability amid ongoing earnings volatility.

However, the negative EBITDA and declining profitability metrics continue to pose challenges for the company’s financial health and investor confidence.

Summary of Key Metrics

To summarise, Themis Medicare Ltd’s stock has reached a new 52-week low of Rs.79.05, reflecting a sustained downtrend marked by four consecutive days of losses and a cumulative decline of -16.37% over this period. The company’s financial performance has deteriorated, with negative quarterly results, shrinking sales, and a significant contraction in profitability. Valuation risks remain elevated, and the stock has underperformed both its sector and the broader market indices over multiple timeframes.

While the company’s debt servicing capacity remains adequate, the overall financial and market indicators point to a challenging environment for Themis Medicare Ltd as of January 2026.

Unlock special upgrade rates for a limited period. Start Saving Now →